RVMD
Revolution Medicines Inc - Ordinary Shares
Company Overview
| Mkt Cap | $11.79B | Price | $99.12 |
| Volume | 1.33M | Change | +0.00% |
| P/E Ratio | -19.7 | Open | $96.47 |
| Revenue | $561.0K | Prev Close | $99.12 |
| Net Income | $-600.1M | 52W Range | $29.17 - $124.49 |
| Div Yield | N/A | Target | $130.81 |
| Overall | 41 | Value | 40 |
| Quality | 47 | Technical | 36 |
No chart data available
About Revolution Medicines Inc - Ordinary Shares
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline includes RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Latest News
Revolution Medicines (RVMD) Receives a Buy from Guggenheim
Analysts Offer Insights on Healthcare Companies: Medpace Holdings (MEDP), Revolution Medicines (RVMD) and Corbus Pharmaceuticals (CRBP)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RVMD | $99.12 | 0% | 1.33M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Revolution Medicines Inc - Ordinary Shares Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW